Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
January 22 2008 - 6:17PM
PR Newswire (US)
TORONTO, Jan. 22 /PRNewswire-FirstCall/ -- Lorus Therapeutics Inc.
(TSX: LOR; AMEX: LRP), a biopharmaceutical company dedicated in the
research and development of pharmaceutical products and
technologies for the management of cancer, announced today that it
has strengthened its management team with the appointment of Mr.
Peter Korth to the post of Chief Financial Officer (CFO). Mr. Korth
has previously held senior financial and business development
positions including CFO in several private and public companies
including DRI Capital (formerly known as Drug Royalty Corp.), Clean
Power Income Fund, TransAlta Corporation and Indal Limited where he
has been responsible for capital and credit markets, transaction
structuring, managing subsidiary reorganizations, risk management
practices as well as international business development in Asia and
Australia. "Mr. Korth brings significant expertise in corporate
finance, investor relations, corporate governance and compliance to
the management team at Lorus," said Dr. Aiping Young, Lorus'
President and CEO. "We believe Lorus will benefit from Peter's
track record in developing and bringing an exemplary combination of
business judgment, professional skills and integrity." About Lorus
Lorus is a biopharmaceutical company focused on the research and
development of novel therapeutics in cancer. Lorus' goal is to
capitalize on its research, preclinical, clinical and regulatory
expertise by developing new drug candidates that can be used,
either alone, or in combination with other drugs, to successfully
manage cancer. Through its own discovery efforts and an acquisition
and in-licensing program, Lorus is building a portfolio of
promising anticancer drugs. Lorus has completed one Phase II and
one Phase III clinical trial. Lorus Therapeutics Inc. is listed on
the Toronto Stock Exchange under the symbol LOR, and on the
American Stock Exchange under the symbol LRP. Forward looking
statements This press release contains forward-looking statements
within the meaning of Canadian and U.S. securities laws. Such
statements include, but are not limited to, statements relating to:
financings and corporate reorganizations, the establishment of
corporate alliances, the Company's plans, objectives, expectations
and intentions and other statements including words such as
"continue", "expect", "intend", "will", "should", "would", "may",
and other similar expressions. Such statements reflect our current
views with respect to future events and are subject to risks and
uncertainties and are necessarily based upon a number of estimates
and assumptions that, while considered reasonable by us are
inherently subject to significant business, economic, competitive,
political and social uncertainties and contingencies. Many factors
could cause our actual results, performance, achievements or the
transactions described in this press release to be materially
different from any future results, performance, achievements or
transactions described in this press release, if at all, that may
be expressed or implied by such forward-looking statements,
including, among others: the progress of negotiations; our ability
to obtain regulatory, security holder and other approvals; our
ability to obtain the capital required for research and operations;
the inherent risks in early stage drug development including
demonstrating efficacy; development time/cost and the regulatory
approval process; the progress of our clinical trials; our ability
to find and enter into agreements with potential partners; our
ability to attract and retain key personnel; changing market
conditions; and other risks detailed from time-to-time in our
ongoing quarterly filings, annual information forms, annual reports
and annual filings with Canadian securities regulators and the
United States Securities and Exchange Commission. Should one or
more of these risks or uncertainties materialize, or should the
assumptions set out in the section entitled "Risk Factors" in our
filings with Canadian securities regulators and the United States
Securities and Exchange Commission underlying those forward-looking
statements prove incorrect, actual results may vary materially from
those described herein. These forward-looking statements are made
as of the date of this press release and we do not intend, and do
not assume any obligation, to update these forward-looking
statements, except as required by law. We cannot assure you that
such statements will prove to be accurate as actual results and
future events could differ materially from those anticipated in
such statements. Investors are cautioned that forward-looking
statements are not guarantees of future performance and accordingly
investors are cautioned not to put undue reliance on
forward-looking statements due to the inherent uncertainty therein.
Lorus Therapeutics' recent press releases are available through the
Company's website at http://www.lorusthera.com/. For Lorus'
regulatory filings on SEDAR, please go to Sedar.com. For SEDAR
filings prior to July 10, 2007 you will find these under the
company profile for 4325231 Canada Inc. DATASOURCE: Lorus
Therapeutics Inc. CONTACT: Lorus Therapeutics Inc., Dr. Saeid
Babaei, (416) 798-1200 ext. 490,
Copyright